No Data
No Data
No Data
No Data
No Data
With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing
Yahoo FinanceApr 22 20:04
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,
GlobeNewswireApr 22 19:00
FYBR, BCRX and SABR Are Among After Hour Movers
Seeking AlphaApr 19 04:56
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil
BioCryst Pharmaceuticals (BCRX) said Wednesday that the Brazilian Health Regulatory Agency has approved Orladeyo, or berotralstat, for the prophylaxis of hereditary angioedema attacks in adults and pe
MT NewswiresApr 17 17:25
BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years
BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Atta
BenzingaApr 17 16:36
Needham: Reiterated the BioCryst Pharma (BCRX.US) rating, adjusted from buy to buy rating, target price of $12.00.
Needham: Reiterated the BioCryst Pharma (BCRX.US) rating, adjusted from buy to buy rating, target price of $12.00.
Zhitong FinanceApr 10 19:11
No Data
No Data